IONS
Ionis Pharmaceuticals, Inc.$46.87-4.58 (-8.90%)Prev Close$51.44·MCap$9.01B·P/E—·Vol4.63M·Yield—
▲
Buys (12M)
1
$1.06M
▼
Sells (12M)
91
$155.11M
◆
Net Activity
Net Seller
$154.05M
●
Active Insiders
20
last 12 mo
Over the past 12 months, insider activity at Ionis Pharmaceuticals, Inc. (IONS) has been dominated by selling, with 1 insider purchase totaling $1.06M and 91 insider sales totaling $155.11M. The most recent insider transaction was by Hayden Michael R (director), who purchased $1.06M worth of shares on Jul 31, 2026. Ionis Pharmaceuticals, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $9.01B.
IONS Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jul 31, 2026 | Hayden Michael R | director | Buy | 20,000 | $52.94 | $1.06M | 24,000+500% |
| Jul 9, 2026 | Diaz Allene M. | director | Sell | 10,111 | $85.42 | $863.6K | 3,811-73% |
| Jul 9, 2026 | BENNETT C FRANK | officer: EVP, Chief Scientific Officer | Sell | 20,536 | $84.95 | $1.74M | 75,018 |
| Jul 9, 2026 | Kordasiewicz Holly B. | officer: EVP, Chief Development Officer | Sell | 362 | $84.30 | $30.5K | 22,096 |
| Jul 6, 2026 | KLEIN JOSEPH III | director | Sell | 11,518 | $79.04 | $910.4K | 22,433-34% |
| Jun 30, 2026 | Schneider Eugene | officer: EVP, Chf Clinical Develop Ofcr | Sell | 26,000 | $81.05 | $2.11M | 77,114-25% |
| Jun 30, 2026 | Baroldi Joseph | officer: EVP, Chief Business Officer | Sell | 5,635 | $80.16 | $451.7K | 4,669-55% |
| Jun 30, 2026 | O'NEIL PATRICK R. | officer: EVP CLO & General Counsel | Sell | 3,069 | $80.00 | $245.5K | 61,470 |
| Jun 26, 2026 | Swayze Eric | officer: EVP Research | Sell | 10,602 | $79.18 | $839.5K | 21,759-33% |
| Jun 26, 2026 | Monia Brett P | director, officer: Chief Executive Officer | Sell | 85,637 | $79.70 | $6.83M | 245,571-26% |
| Jun 16, 2026 | Kordasiewicz Holly B. | officer: EVP, Chief Development Officer | Sell | 60,846 | $73.41 | $4.47M | 42,300-59% |
| Jun 16, 2026 | BERTHELSEN SPENCER R | director | Sell | 8,000 | $73.49 | $587.9K | 156,013 |
| Jun 3, 2026 | BERTHELSEN SPENCER R | director | Sell | 8,000 | $75.67 | $605.4K | 156,013 |
| May 15, 2026 | Monia Brett P | director, officer: Chief Executive Officer | Sell | 4,536 | $78.49 | $356.0K | 242,662 |
| May 6, 2026 | LOSCALZO JOSEPH | director | Sell | 77,289 | $75.06 | $5.80M | 54,111-59% |
| May 5, 2026 | KLEIN JOSEPH III | director | Sell | 10,111 | $73.51 | $743.2K | 12,445-45% |
| Apr 30, 2026 | Baroldi Joseph | officer: EVP, Chief Business Officer | Sell | 1,626 | $71.79 | $116.7K | 44,909 |
| Apr 17, 2026 | PARSHALL B LYNNE | director | Sell | 5,000 | $76.27 | $381.4K | 51,878 |
| Apr 17, 2026 | Jenne Kyle | officer: EVP, Chf GL Pdt Str Ofcr | Sell | 4,902 | $75.17 | $368.5K | 23,713 |
| Apr 17, 2026 | Baroldi Joseph | officer: EVP, Chief Business Officer | Sell | 5,619 | $74.56 | $419.0K | 46,535 |
| Apr 17, 2026 | Birchler Brian | officer: EVP, Corp and Development Ops | Sell | 973 | $75.04 | $73.0K | 67,500 |
| Apr 2, 2026 | Devers Shannon L. | officer: EVP, Chief Human Resources Ofc | Sell | 6,193 | $74.05 | $458.6K | 16,348-27% |
| Apr 2, 2026 | KLEIN JOSEPH III | director | Sell | 22,321 | $75.55 | $1.69M | 13,230-63% |
| Mar 23, 2026 | Schneider Eugene | officer: EVP, Chf Clinical Develop Ofcr | Sell | 5,812 | $70.97 | $412.5K | 63,890 |
| Mar 18, 2026 | HOUGEN ELIZABETH L | officer: EVP, Finance & CFO | Sell | 225,220 | $72.43 | $16.31M | 102,272-69% |
| Mar 5, 2026 | Baroldi Joseph | officer: EVP, Chief Business Officer | Sell | 6,421 | $79.73 | $511.9K | 41,317 |
| Mar 5, 2026 | BENNETT C FRANK | officer: EVP, Chief Scientific Officer | Sell | 85,089 | $79.23 | $6.74M | 94,043-48% |
| Mar 5, 2026 | Devers Shannon L. | officer: EVP, Chief Human Resources Ofc | Sell | 20,106 | $79.40 | $1.60M | 28,326-42% |
| Mar 5, 2026 | Diaz Allene M. | director | Sell | 54,878 | $79.35 | $4.35M | 19,424-74% |
| Mar 5, 2026 | KLEIN JOSEPH III | director | Sell | 21,332 | $79.51 | $1.70M | 18,820-53% |
| Mar 5, 2026 | LOSCALZO JOSEPH | director | Sell | 1,032 | $80.26 | $82.8K | 36,330 |
| Feb 13, 2026 | PARSHALL B LYNNE | director | Sell | 5,000 | $82.72 | $413.6K | 56,344 |
| Feb 13, 2026 | Swayze Eric | officer: EVP Research | Sell | 31,284 | $81.76 | $2.56M | 38,312-45% |
| Feb 11, 2026 | PARSHALL B LYNNE | Director | Sell | 5,000 | $82.72 | $413.6K | 0 |
| Feb 10, 2026 | Monia Brett P | director, officer: Chief Executive Officer | Sell | 29,430 | $85.79 | $2.52M | 254,497 |
| Feb 6, 2026 | Monia Brett P | Chief Executive Officer | Sell | 29,430 | $85.79 | $2.52M | 0 |
| Feb 4, 2026 | BENNETT C FRANK | officer: EVP, Chief Scientific Officer | Sell | 36,463 | $82.79 | $3.02M | 80,293-31% |
| Feb 2, 2026 | Baroldi Joseph | officer: EVP, Chief Business Officer | Sell | 5,296 | $82.96 | $439.4K | 45,413 |
| Feb 2, 2026 | BENNETT C FRANK | officer: EVP, Chief Scientific Officer | Sell | 90,974 | $82.93 | $7.54M | 100,293-48% |
| Feb 2, 2026 | Birchler Brian | officer: EVP, Corp and Development Ops | Sell | 6,179 | $83.03 | $513.0K | 66,247 |
| Feb 2, 2026 | HOUGEN ELIZABETH L | officer: EVP, Finance & CFO | Sell | 6,988 | $83.24 | $581.7K | 132,881 |
| Feb 2, 2026 | Monia Brett P | director, officer: Chief Executive Officer | Sell | 62,970 | $82.72 | $5.21M | 283,927 |
| Feb 2, 2026 | O'NEIL PATRICK R. | officer: EVP CLO & General Counsel | Sell | 6,179 | $83.53 | $516.2K | 71,983 |
| Feb 2, 2026 | Schneider Eugene | officer: EVP, Chf Clinical Develop Ofcr | Sell | 6,179 | $83.45 | $515.6K | 69,702 |
| Feb 2, 2026 | Swayze Eric | officer: EVP Research | Sell | 6,179 | $82.93 | $512.4K | 47,747 |
| Jan 29, 2026 | Baroldi Joseph | EVP, Chief Business Officer | Sell | 5,296 | $82.96 | $439.4K | 0 |
| Jan 29, 2026 | BENNETT C FRANK | EVP, Chief Scientific Officer | Sell | 5,885 | $82.95 | $488.1K | 0 |
| Jan 29, 2026 | Birchler Brian | EVP, Corp and Development Ops | Sell | 6,179 | $83.03 | $513.0K | 0 |
| Jan 29, 2026 | HOUGEN ELIZABETH L | EVP, Finance & CFO | Sell | 6,988 | $83.24 | $581.7K | 0 |
| Jan 29, 2026 | Monia Brett P | Chief Executive Officer | Sell | 62,970 | $82.72 | $5.21M | 0 |
Showing 1–50 of 122
1 / 3
IONS Insider Buying Activity
The following table shows recent insider purchases of Ionis Pharmaceuticals, Inc. (IONS) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jul 31, 2026 | Hayden Michael R | director | Buy | 20,000 | $52.94 | $1.06M | 24,000+500% |
IONS Insider Selling Activity
The following table shows recent insider sales of Ionis Pharmaceuticals, Inc. (IONS) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jul 9, 2026 | Diaz Allene M. | director | Sell | 10,111 | $85.42 | $863.6K | 3,811-73% |
| Jul 9, 2026 | BENNETT C FRANK | officer: EVP, Chief Scientific Officer | Sell | 20,536 | $84.95 | $1.74M | 75,018 |
| Jul 9, 2026 | Kordasiewicz Holly B. | officer: EVP, Chief Development Officer | Sell | 362 | $84.30 | $30.5K | 22,096 |
| Jul 6, 2026 | KLEIN JOSEPH III | director | Sell | 11,518 | $79.04 | $910.4K | 22,433-34% |
| Jun 30, 2026 | Schneider Eugene | officer: EVP, Chf Clinical Develop Ofcr | Sell | 26,000 | $81.05 | $2.11M | 77,114-25% |
| Jun 30, 2026 | Baroldi Joseph | officer: EVP, Chief Business Officer | Sell | 5,635 | $80.16 | $451.7K | 4,669-55% |
| Jun 30, 2026 | O'NEIL PATRICK R. | officer: EVP CLO & General Counsel | Sell | 3,069 | $80.00 | $245.5K | 61,470 |
| Jun 26, 2026 | Swayze Eric | officer: EVP Research | Sell | 10,602 | $79.18 | $839.5K | 21,759-33% |
| Jun 26, 2026 | Monia Brett P | director, officer: Chief Executive Officer | Sell | 85,637 | $79.70 | $6.83M | 245,571-26% |
| Jun 16, 2026 | Kordasiewicz Holly B. | officer: EVP, Chief Development Officer | Sell | 60,846 | $73.41 | $4.47M | 42,300-59% |
| Jun 16, 2026 | BERTHELSEN SPENCER R | director | Sell | 8,000 | $73.49 | $587.9K | 156,013 |
| Jun 3, 2026 | BERTHELSEN SPENCER R | director | Sell | 8,000 | $75.67 | $605.4K | 156,013 |
| May 15, 2026 | Monia Brett P | director, officer: Chief Executive Officer | Sell | 4,536 | $78.49 | $356.0K | 242,662 |
| May 6, 2026 | LOSCALZO JOSEPH | director | Sell | 77,289 | $75.06 | $5.80M | 54,111-59% |
| May 5, 2026 | KLEIN JOSEPH III | director | Sell | 10,111 | $73.51 | $743.2K | 12,445-45% |
| Apr 30, 2026 | Baroldi Joseph | officer: EVP, Chief Business Officer | Sell | 1,626 | $71.79 | $116.7K | 44,909 |
| Apr 17, 2026 | PARSHALL B LYNNE | director | Sell | 5,000 | $76.27 | $381.4K | 51,878 |
| Apr 17, 2026 | Jenne Kyle | officer: EVP, Chf GL Pdt Str Ofcr | Sell | 4,902 | $75.17 | $368.5K | 23,713 |
| Apr 17, 2026 | Baroldi Joseph | officer: EVP, Chief Business Officer | Sell | 5,619 | $74.56 | $419.0K | 46,535 |
| Apr 17, 2026 | Birchler Brian | officer: EVP, Corp and Development Ops | Sell | 973 | $75.04 | $73.0K | 67,500 |
| Apr 2, 2026 | Devers Shannon L. | officer: EVP, Chief Human Resources Ofc | Sell | 6,193 | $74.05 | $458.6K | 16,348-27% |
| Apr 2, 2026 | KLEIN JOSEPH III | director | Sell | 22,321 | $75.55 | $1.69M | 13,230-63% |
| Mar 23, 2026 | Schneider Eugene | officer: EVP, Chf Clinical Develop Ofcr | Sell | 5,812 | $70.97 | $412.5K | 63,890 |
| Mar 18, 2026 | HOUGEN ELIZABETH L | officer: EVP, Finance & CFO | Sell | 225,220 | $72.43 | $16.31M | 102,272-69% |
| Mar 5, 2026 | Baroldi Joseph | officer: EVP, Chief Business Officer | Sell | 6,421 | $79.73 | $511.9K | 41,317 |
| Mar 5, 2026 | BENNETT C FRANK | officer: EVP, Chief Scientific Officer | Sell | 85,089 | $79.23 | $6.74M | 94,043-48% |
| Mar 5, 2026 | Devers Shannon L. | officer: EVP, Chief Human Resources Ofc | Sell | 20,106 | $79.40 | $1.60M | 28,326-42% |
| Mar 5, 2026 | Diaz Allene M. | director | Sell | 54,878 | $79.35 | $4.35M | 19,424-74% |
| Mar 5, 2026 | KLEIN JOSEPH III | director | Sell | 21,332 | $79.51 | $1.70M | 18,820-53% |
| Mar 5, 2026 | LOSCALZO JOSEPH | director | Sell | 1,032 | $80.26 | $82.8K | 36,330 |
| Feb 13, 2026 | PARSHALL B LYNNE | director | Sell | 5,000 | $82.72 | $413.6K | 56,344 |
| Feb 13, 2026 | Swayze Eric | officer: EVP Research | Sell | 31,284 | $81.76 | $2.56M | 38,312-45% |
| Feb 11, 2026 | PARSHALL B LYNNE | Director | Sell | 5,000 | $82.72 | $413.6K | 0 |
| Feb 10, 2026 | Monia Brett P | director, officer: Chief Executive Officer | Sell | 29,430 | $85.79 | $2.52M | 254,497 |
| Feb 6, 2026 | Monia Brett P | Chief Executive Officer | Sell | 29,430 | $85.79 | $2.52M | 0 |
| Feb 4, 2026 | BENNETT C FRANK | officer: EVP, Chief Scientific Officer | Sell | 36,463 | $82.79 | $3.02M | 80,293-31% |
| Feb 2, 2026 | Baroldi Joseph | officer: EVP, Chief Business Officer | Sell | 5,296 | $82.96 | $439.4K | 45,413 |
| Feb 2, 2026 | BENNETT C FRANK | officer: EVP, Chief Scientific Officer | Sell | 90,974 | $82.93 | $7.54M | 100,293-48% |
| Feb 2, 2026 | Birchler Brian | officer: EVP, Corp and Development Ops | Sell | 6,179 | $83.03 | $513.0K | 66,247 |
| Feb 2, 2026 | HOUGEN ELIZABETH L | officer: EVP, Finance & CFO | Sell | 6,988 | $83.24 | $581.7K | 132,881 |
| Feb 2, 2026 | Monia Brett P | director, officer: Chief Executive Officer | Sell | 62,970 | $82.72 | $5.21M | 283,927 |
| Feb 2, 2026 | O'NEIL PATRICK R. | officer: EVP CLO & General Counsel | Sell | 6,179 | $83.53 | $516.2K | 71,983 |
| Feb 2, 2026 | Schneider Eugene | officer: EVP, Chf Clinical Develop Ofcr | Sell | 6,179 | $83.45 | $515.6K | 69,702 |
| Feb 2, 2026 | Swayze Eric | officer: EVP Research | Sell | 6,179 | $82.93 | $512.4K | 47,747 |
| Jan 29, 2026 | Baroldi Joseph | EVP, Chief Business Officer | Sell | 5,296 | $82.96 | $439.4K | 0 |
| Jan 29, 2026 | BENNETT C FRANK | EVP, Chief Scientific Officer | Sell | 5,885 | $82.95 | $488.1K | 0 |
| Jan 29, 2026 | Birchler Brian | EVP, Corp and Development Ops | Sell | 6,179 | $83.03 | $513.0K | 0 |
| Jan 29, 2026 | HOUGEN ELIZABETH L | EVP, Finance & CFO | Sell | 6,988 | $83.24 | $581.7K | 0 |
| Jan 29, 2026 | Monia Brett P | Chief Executive Officer | Sell | 62,970 | $82.72 | $5.21M | 0 |
IONS Insiders
Similar Stocks to IONS
VRTX
Vertex Pharmaceuticals Incorporated
$513.52-1.17%
$132.26B
REGN
Regeneron Pharmaceuticals, Inc.
$772.87-2.63%
$83.21B
MRNA
Moderna, Inc.
$142.93-2.49%
$57.13B
RVMD
Revolution Medicines, Inc.
$204.47-0.31%
$44.15B
INSM
Insmed Incorporated
$119.56-4.63%
$28.05B
INCY
Incyte Corporation
$121.65-0.43%
$24.62B
UTHR
United Therapeutics Corporation
$500.44-0.42%
$21.10B
NBIX
Neurocrine Biosciences, Inc.
$150.44-4.31%
$15.71B